Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up
Shared Decision Making, Good Disease Control Are Key Components of JIA Management
New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management
Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA
Clinical Remission Should Be Target of JIA Treatment: Task Force
TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
Year in Review: Expert Covers Year’s Key Clinical Findings
Juvenile-Onset Arthritis Bodes Worse Pregnancy Outcomes
